TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.

TRACON Pharmaceuticals Trading Down 21.7 %

NASDAQ TCON opened at $0.07 on Tuesday. TRACON Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $14.75. The stock has a market cap of $235,290.00, a price-to-earnings ratio of 0.10 and a beta of 1.35. The company’s 50 day moving average is $0.33 and its two-hundred day moving average is $2.21.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.